Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan.
Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan; Center for Clinical Management Research, Department of Veterans Affairs, Ann Arbor, Michigan.
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242. doi: 10.1016/j.amepre.2017.12.022.
At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include providing free and easy-to-access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types-including behavioral health counselors and other non-physicians in specialty and non-specialty settings.
This article is part of a supplement entitled The Behavioral Health Workforce: Planning, Practice, and Preparation, which is sponsored by the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
美国至少有 230 万人患有阿片类药物使用障碍,但只有不到 40%的人接受循证治疗。作为药物辅助治疗的一部分,丁丙诺啡具有很高的潜力来解决这一差距,因为它被批准用于非专科门诊环境,有效促进戒除毒瘾,并且具有成本效益。然而,只有不到 4%的持照医生被批准开具丁丙诺啡治疗阿片类药物使用障碍,大约 47%的县没有丁丙诺啡豁免医生。现有政策造成了丁丙诺啡提供和获取方面的劳动力障碍。由于劳动力障碍,提供者不愿意开丁丙诺啡,这些障碍包括:(1)在阿片类药物使用障碍治疗方面的培训和教育不足;(2)缺乏机构和临床医生同行的支持;(3)医疗协调不善;(4)提供者耻辱感;(5)私人和公共保险公司的报销不足;(6)获得在非成瘾专科治疗环境中开具丁丙诺啡所需豁免的监管障碍。解决这些提供者劳动力障碍的政策途径包括为提供者提供关于阿片类药物使用障碍和药物辅助治疗的免费且易于获取的教育,取消对有资格开具受控物质的人的丁丙诺啡豁免要求,执行保险均等要求,将基于证据的药物辅助治疗作为基本健康福利进行覆盖,并为医疗协调提供财务激励,包括行为健康顾问和其他在专科和非专科环境中的非医师。
本文是题为“行为健康劳动力:规划、实践和准备”的补充内容的一部分,该补充内容由美国卫生与公众服务部下属的物质滥用和精神卫生服务管理局以及卫生资源和服务管理局赞助。